The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68:394–424.
   Google Scholar
• Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer 2012;118:5463–72.
   PubMed Web of Science ®Google Scholar
• Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 2017;161:279–87.
   PubMed Web of Science ®Google Scholar
• Guney Eskiler G, Cecener G, Egeli U, Tunca B. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS 2018;126:371–9.
   PubMed Web of Science ®Google Scholar
• Ye S, Xu Y, Wang L, et al. Estrogen-related receptor α (ERRα) and G protein-coupled estrogen receptor (GPER) synergistically indicate poor prognosis in patients with triple-negative breast cancer . Onco Targets Ther 2020;13:8887–99.
   PubMed Web of Science ®Google Scholar
• Manna S, Bostner J, Sun Y, et al. ERRα is a marker of tamoxifen response and survival in triple-negative breast cancer . Clin Cancer Res 2016;22:1421–31.
   PubMed Web of Science ®Google Scholar
• Huss JM, Kopp RP, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1alpha (pgc-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within pgc-1alpha. J Biol Chem 2002;277:40265–74.
   PubMed Web of Science ®Google Scholar
• Seth A, Steel JH, Nichol D, et al. The transcriptional corepressor rip140 regulates oxidative metabolism in skeletal muscle. Cell Metab 2007;6:236–45.
   PubMed Web of Science ®Google Scholar
• Chang CY, McDonnell DP. Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clin Cancer Res 2012;18:6089–95.
   PubMed Web of Science ®Google Scholar
• Lu Y, Li Q, Chen L, Shi X. XCT790 inhibits rat vascular smooth muscle cells proliferation through down-regulating the expression of estrogen-related receptor alpha . Acta Pharmaceutica Sinica 2014;49:190–7.
   PubMedGoogle Scholar
• Zhang LD, Chen L, Zhang M, et al. Downregulation of ERRα inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/Akt/STAT3 signaling pathway . Eur J Pharmacol 2015;769:167–76.
   PubMed Web of Science ®Google Scholar
• Stein RA, Chang CY, Kazmin DA, et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 2008;68:8805–12.
   PubMed Web of Science ®Google Scholar
• Vargas G, Bouchet M, Bouazza L, et al. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene 2019;38:950–64.
   PubMed Web of Science ®Google Scholar
• Stein RA, Gaillard S, McDonnell DP. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:106–12.
   PubMed Web of Science ®Google Scholar
• Bianco S, Lanvin O, Tribollet V, et al. Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. J Biol Chem 2009;284:23286–92.
   PubMed Web of Science ®Google Scholar
• Busch BB, Stevens WC Jr, Martin R, et al. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. J Med Chem 2004;47:5593–6.
   PubMedGoogle Scholar
• Kallen J, Lattmann R, Beerli R, et al. Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J Biol Chem 2007;282:23231–9.
   PubMed Web of Science ®Google Scholar
• Patch RJ, Searle LL, Kim AJ, et al. Identification of diaryl ether-based ligands for estrogen-related receptor alpha as potential antidiabetic agents. J Med Chem 2011;54:788–808.
   PubMed Web of Science ®Google Scholar
• Patch RJ, Huang H, Patel S, et al. Indazole-based ligands for estrogen-related receptor alpha as potential anti-diabetic agents. Eur J Med Chem 2017;138:830–53.
   PubMed Web of Science ®Google Scholar
• Xu S, Zhuang X, Pan X, et al. 1-phenyl-4-benzoyl-1h-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor α. J Med Chem 2013;56:4631–40.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu P, Chen H, et al. Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer. Eur J Pharmacol 2016;789:439–48.
   PubMed Web of Science ®Google Scholar
• Du Y, Song L, Zhang L, et al. The discovery of novel, potent err-alpha inverse agonists for the treatment of triple negative breast cancer. Eur J Med Chem 2017;136:457–67.
   PubMed Web of Science ®Google Scholar
• Kallen J, Schlaeppi JM, Bitsch F, et al. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (erralpha): crystal structure of erralpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. J Biol Chem 2004;279:49330–7.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Oda T, Chang M-R, et al. Synthesis and antitumor activity of fused quinoline derivatives. Iv. Novel 11-aminoindolo[3,2-b]quinolines. Chem Pharm Bull 1997;45:406–11.
   PubMed Web of Science ®Google Scholar
• Rassadin VA, Grosheva DS, Arefeva IA, et al. Access to a wide range of sultams by cyclodialkylation of α-substituted methanesulfonanilides. Eur J Org Chem 2012; 2012:5028–37.
   Web of Science ®Google Scholar